

sanofi

•

Sanofi – DYSLIPIDEMIA

ESR Areas of Interest

•

Aug 2023

Dyslipidemia - Scope of Interests

Areas of Interest	Gap/Unmet Need Addressed
Prevention of 1 st MACE in Very High-Risk Patients	• Demonstrate the efficacy and safety of Alirocumab/PCSK9i
ACS pathway initiatives	• Impact of ACS pathway initiatives in <u>hospital settings</u> on optimising LDL-C goal achievement • Impact of ACS pathway initiatives in <u>patient settings</u> on optimising LDL-C goal achievement
ACS patients	• Impact of early vs late initiation of alirocumab, in addition to intensive combination LLT, to reduce MACE